ReviewHeart failure reviews2007
Signaling pathways in ischemic preconditioning.
Review in Heart failure reviews, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 129 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
129 citing papers in PubMed, 2 syntheses or guidelines pooled it, 313 citations in OpenAlex.
- Coenzyme QFrontiers in cardiovascular medicine · 2022Pooled it
- Pharmacological attenuation of myocardial reperfusion injury in a closed-chest porcine model: a systematic review.Journal of cardiovascular translational research · 2014Pooled it
- Effects of 8-week ischemic preconditioning on swimming performance and power output in male 100-m freestyle swimmers: a randomized controlled trial.European journal of applied physiology · 2026Trial
- Ischemic preconditioning enhances energy supply during frequency speed kick test in Taekwondo athletes: A randomized crossover study.PloS one · 2026Trial
- Effects of Acute and Repeated Ischemic Preconditioning on Recovery from Muscle Fatigue after High-Intensity Swim Training in Male Amateur Swimmers.Journal of sports science & medicine · 2025Trial
- Ischemic preconditioning enhances autonomic nervous system modulation during frequency speed of kick test in taekwondo athletes: a randomized crossover study.BMC sports science, medicine & rehabilitation · 2026Article
- Novel Selective Cardiac Myosin-Targeted Inhibitors Alleviate Myocardial Ischaemia-Reperfusion Injury.Cardiovascular drugs and therapy · 2026Article
- Importance of STAT3 signaling in preeclampsia (Review).International journal of molecular medicine · 2025Review
- Ex vivo rat heart normothermic perfusion with intermittent low flow and triiodothyronine.Frontiers in cardiovascular medicine · 2025Article
- Oxidative Metabolism in Brain Ischemia and Preconditioning: Two Sides of the Same Coin.Antioxidants (Basel, Switzerland) · 2024Review
- Identification of the serum metabolomic profile for acute ischemic preconditioning in athletes.Frontiers in physiology · 2024Article
- Is Intrinsic Cardioprotection a Laboratory Phenomenon or a Clinically Relevant Tool to Salvage the Failing Heart?International journal of molecular sciences · 2023Review
- Metabolite signaling in the heart.Nature cardiovascular research · 2023Review
- Slowly activating voltage-gated potassium current potentiation by ML277 is a novel cardioprotective intervention.PNAS nexus · 2023Article
- Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCε-Stat3 pathway.Journal of advanced research · 2023Article
- Prostaglandin EHeart and vessels · 2023Article
- Purinergic signaling in myocardial ischemia-reperfusion injury.Purinergic signalling · 2023Review
- Pathways for Cardioprotection in Perspective: Focus on Remote Conditioning and Extracellular Vesicles.Biology · 2023Review
- Maternal use of methamphetamine induces sex-dependent changes in myocardial gene expression in adult offspring.Physiological reports · 2022Article
- Cardioprotective Signaling Pathways in Obese Mice Submitted to Regular Exercise: Effect on Oxysterols.International journal of molecular sciences · 2022Article
69 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic preconditioning renders the heart resistant to infarction from ischemia/reperfusion. Over the past two decades a great deal has been learned about preconditioning's mechanism. Adenosine, bradykinin, and opioids act in parallel to trigger the preconditioned state and do so by activating PKC. While adenosine couples directly to PKC through the phospholipases, bradykinin and opioids do so through a complex pathway that includes in order: phosphatidylinositol 3-kinase (PI3-kinase), Akt, nitric oxide synthase, guanylyl cyclase, PKG, opening of mitochondrial K(ATP) channels, and activation of PKC by redox signaling. There are even differences between the opioid and bradykinin coupling as the former activates PI3-kinase through transactivation of the epidermal growth factor receptor while the latter has an unknown coupling mechanism. Protection stems from inhibition of formation of mitochondrial permeability transition pores early in reperfusion through activation of the survival kinases, Akt and ERK. These kinases are activated as a result of PKC somehow promoting signaling from adenosine A(2) receptors early in reperfusion. The survival kinases are thought to inhibit pore formation by phosphorylating GSK-3beta. The reperfused heart requires the support of the protective signals for only about an hour after which the ischemic injury is repaired and the signals are no longer needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.